2-cyclopropyl-1,3-thiazol-5-amine | 942631-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-cyclopropyl-1,3-thiazol-5-amine
• 英文别名: 2-Cyclopropylthiazol-5-amine
• CAS: 942631-64-3
• 化学式: C₆H₈N₂S
• 分子量: 140.209
• InChiKey: UGDFEZVEPWHLLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-cyclopropyl-1,3-thiazol-5-amine 、 5-[[[3-(三氟甲基)苯基]羰基]氨基]-2-氯苯甲酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-N-(2-cyclopropyl-1,3-thiazol-5-yl)-5-{[3-(trifluoromethyl)benzoyl]amino}benzamide
  参考文献：
  名称：

  Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

  摘要：

  The bisamide class of kinase inhibitors was identified as being active against CSF-1R. The synthesis and SAR of pyridyl and thiazolyl bisamides is reported, along with the pharmacokinetic properties and in vivo activity of selected examples. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.093
• 作为产物：
  描述：

  Methyl cyclopropanecarbodithioate 、 氨基乙腈硫酸氢盐 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2-cyclopropyl-1,3-thiazol-5-amine
  参考文献：
  名称：

  Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

  摘要：

  The bisamide class of kinase inhibitors was identified as being active against CSF-1R. The synthesis and SAR of pyridyl and thiazolyl bisamides is reported, along with the pharmacokinetic properties and in vivo activity of selected examples. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.093

文献信息

• [EN] MACROCYCLIC SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SÉRINE PROTÉASE
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2009014730A1

  公开（公告）日：2009-01-29

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，Formula I的药物组合物，以及其制备方法。还提供了它们用于治疗宿主HCV感染的方法。
• [EN] 5-AMINO- 4-HYDROXYPENTOYL AMIDES<br/>[FR] 5-AMINO-4-HYDROXYPENTOYLAMIDES
  申请人：TIBOTEC PHARM LTD

  公开号：WO2011070131A1

  公开（公告）日：2011-06-16

  HIV inhibitors of formula (I) wherein R1 is halo, C1-4alkoxy, trifluoromethoxy; R2 is a group of formula (A); R3 is a group of formula (B); R4 is a group of formula (C); n is 0 or 1; A is CH or N; R5 and R6 are hydrogen, C1-4alkyl, halo; R7 and R8 are C1-4alkyl or C1-4alkoxyC1-4alkyl; R9 is C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; R10 is hydrogen, C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.

  公式(I)中的HIV抑制剂，其中R1是卤素、C1-4烷氧基、三氟甲氧基；R2是公式(A)的基团；R3是公式(B)的基团；R4是公式(C)的基团；n是0或1；A是CH或N；R5和R6是氢、C1-4烷基、卤素；R7和R8是C1-4烷基或C1-4烷氧基C1-4烷基；R9是C1-4烷基、环丙基、三氟甲基、C1-4烷氧基或二甲氨基；R10是氢、C1-4烷基、环丙基、三氟甲基、C1-4烷氧基或二甲氨基；药用可接受的附加盐和溶剂化物；含有这些化合物的药用组合物以及制备这些化合物的方法。
• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。
• Chemical Compounds-149
  申请人：Aquila Brian

  公开号：US20080312206A1

  公开（公告）日：2008-12-18

  The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及一种化合物，或其药学上可接受的盐，其化学式如下，具有CSF 1R激酶抑制活性，因此在抗癌活性方面有用，并且在人或动物体的治疗方法中有用。本发明还涉及制造所述化合物的过程，含有它们的制药组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1966174A1

  公开（公告）日：2008-09-10